Ser511
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.5
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser511  -  WAC (human)

Site Information
QQGHEPVsPRSLQRs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 470738
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 )
Disease tissue studied:
breast cancer ( 6 , 7 , 18 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 3 ) , luminal A breast cancer ( 3 ) , luminal B breast cancer ( 3 ) , breast cancer, surrounding tissue ( 3 ) , breast cancer, triple negative ( 3 , 6 ) , cervical cancer ( 28 ) , cervical adenocarcinoma ( 28 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 17 ) , acute megakaryoblastic leukemia (M7) ( 17 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 17 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 17 ) , acute myeloblastic leukemia, without maturation (M1) ( 17 ) , lung cancer ( 10 , 11 , 12 , 18 ) , non-small cell lung cancer ( 11 , 18 ) , non-small cell lung adenocarcinoma ( 10 , 11 , 12 ) , non-small cell squamous cell lung carcinoma ( 10 ) , lymphoma ( 8 ) , B cell lymphoma ( 17 ) , non-Hodgkin's lymphoma ( 17 ) , follicular lymphoma ( 8 ) , mantle cell lymphoma ( 8 ) , ovarian cancer ( 6 ) , multiple myeloma ( 17 )
Relevant cell line - cell type - tissue:
293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 25 ) , 293 (epithelial) [AT1 (human), transfection] ( 24 ) , A498 (renal) ( 27 ) , A549 (pulmonary) ( 13 ) , AML-193 (monocyte) ( 17 ) , breast ( 3 , 6 ) , BT-549 (breast cell) ( 18 ) , Cal-12T (pulmonary) ( 11 ) , CMK (megakaryoblast) ( 17 ) , CTS (myeloid) ( 17 ) , DOHH2 ('B lymphocyte, precursor') ( 17 ) , endothelial-aorta ( 19 ) , FL-18 (B lymphocyte) ( 8 ) , GM00130 (B lymphocyte) ( 26 ) , H2009 (pulmonary) ( 18 ) , H2077 (pulmonary) ( 18 ) , H2887 (pulmonary) ( 18 ) , H322M (pulmonary) ( 18 ) , HCC1359 (pulmonary) ( 18 ) , HCC15 (pulmonary) ( 10 ) , HCC1937 (breast cell) ( 18 ) , HCC2279 (pulmonary) ( 18 ) , HCC366 (pulmonary) ( 18 ) , HCC4006 (pulmonary) ( 18 ) , HCC44 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 18 ) , HEL (erythroid) ( 17 ) , HeLa (cervical) ( 2 , 5 , 16 , 23 , 29 , 30 ) , HeLa S3 (cervical) ( 28 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 7 ) , HMLER ('stem, breast cancer') ( 7 ) , HOP62 (pulmonary) ( 18 ) , HUES-9 ('stem, embryonic') ( 22 ) , Jurkat (T lymphocyte) ( 14 , 21 ) , K562 (erythroid) ( 16 , 29 ) , Kasumi-1 (myeloid) ( 17 ) , KG-1 (myeloid) ( 17 ) , liver ( 9 ) , LOU-NH91 (squamous) ( 10 ) , lung ( 10 , 11 , 12 ) , MCF-7 (breast cell) ( 18 ) , MDA-MB-231 (breast cell) ( 18 ) , MV4-11 (macrophage) ( 17 ) , NCI-H1395 (pulmonary) ( 18 ) , NCI-H1437 (pulmonary) ( 11 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H1703 (squamous) ( 10 ) , NCI-H2030 (pulmonary) ( 18 ) , NCI-H2073 (pulmonary) ( 10 ) , NCI-H2172 (pulmonary) ( 18 ) , NCI-H2342 (pulmonary) ( 10 ) , NCI-H2405 (pulmonary) ( 11 ) , NCI-H322 (pulmonary) ( 18 ) , NCI-H520 (squamous) ( 18 ) , OPM-2 (plasma cell) ( 17 ) , ovary ( 6 ) , P31/FUJ (erythroid) ( 17 ) , PC9 (pulmonary) ( 18 ) , RL ('B lymphocyte, precursor') ( 17 ) , RPMI-8266 (plasma cell) ( 17 ) , SU-DHL-6 (B lymphocyte) ( 17 ) , U266 (plasma cell) ( 17 ) , UPN-1 (B lymphocyte) ( 8 ) , Vero E6-S ('epithelial, kidney') ( 1 )

Upstream Regulation
Treatments:
dasatinib ( 29 )

References 

1

Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182
32645325   Curated Info

2

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

3

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

4

Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610
27184836   Curated Info

5

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

6

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

7

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

8

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

9

Bian Y, et al. (2014) An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics 96, 253-62
24275569   Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

13

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

14

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

15

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

16

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

17

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

18

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

19

Verano-Braga T, et al. (2012) Time-resolved quantitative phosphoproteomics: new insights into Angiotensin-(1-7) signaling networks in human endothelial cells. J Proteome Res 11, 3370-81
22497526   Curated Info

20

Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25
22424773   Curated Info

21

Guo A (2011) CST Curation Set: 12058; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR
Curated Info

22

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

23

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

24

Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304
20686112   Curated Info

25

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

26

Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23
20164059   Curated Info

27

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

28

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

29

Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808
19651622   Curated Info

30

Olsen JV, et al. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-48
17081983   Curated Info